The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Low-dose gemcitabine doxorubicin and docetaxel combination in patients with advanced/unresectable/metastatic sarcoma who failed prior chemotherapy: Updated analysis.
Vivek Narasimhan
No relevant relationships to disclose
James Hu
No relevant relationships to disclose
Kamalesh Kumar Sankhala
No relevant relationships to disclose
Doris V. Quon
No relevant relationships to disclose
Lawrence Menendez
No relevant relationships to disclose
Lita Fernandez
No relevant relationships to disclose
Victoria S Chua
No relevant relationships to disclose
Sant P. Chawla
No relevant relationships to disclose